CoChat
Sign Up
Cited by 117

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Annexin A2 Is a Natural Extrahepatic Inhibitor of the PCSK9-Induced LDL Receptor Degradation

Seidah, Nabil G., Poirier, Steve, Denis, Maxime, Parker, Rex, Miao, Bowman, Mapelli, Claudio, Prat, Annik, Wassef, Hanny, Davignon, Jean, Hajjar, Katherine A., Mayer, Gaétan·2012·PLoS ONE
DOI 10.1371/journal.pone.0041865PMC PMC3407131
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0041865

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 74

  1. M Varret, 2008, Genetic heterogeneity of autosomal dominant hypercholesterolemia., Clin Genet, 73, 1, 10.1111/j.1399-0004.2007.00915.x · DOI
  2. A Cenarro, 2011, A presumptive new locus for autosomal dominant hypercholesterolemia mapping to 8q24.22., Clin Genet, 79, 475, 10.1111/j.1399-0004.2010.01485.x · DOI · Paper page
  3. A Marques-Pinheiro, 2010, A fourth locus for autosomal dominant hypercholesterolemia maps at 16q22.1., Eur J Hum Genet, 18, 1236, 10.1038/ejhg.2010.94 · DOI · Paper page
  4. NG Seidah, 2003, The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation., Proc Natl Acad Sci U S A, 100, 928, 10.1073/pnas.0335507100 · DOI · Paper page
  5. NG Seidah, 2008, The activation and physiological functions of the proprotein convertases., Int J Biochem Cell Biol, 40, 1111, 10.1016/j.biocel.2008.01.030 · DOI · Paper page
  6. M Abifadel, 2003, Mutations in PCSK9 cause autosomal dominant hypercholesterolemia., Nat Genet, 34, 154, 10.1038/ng1161 · DOI · Paper page
  7. S Rashid, 2005, Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9., Proc Natl Acad Sci U S A, 102, 5374, 10.1073/pnas.0501652102 · DOI · Paper page
  8. KN Maxwell, 2004, Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype., Proc Natl Acad Sci U S A, 101, 7100, 10.1073/pnas.0402133101 · DOI · Paper page
  9. A Zaid, 2008, Proprotein convertase subtilisin/kexin type 9 (PCSK9): Hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration., Hepatology, 48, 646, 10.1002/hep.22354 · DOI · Paper page
  10. D Cunningham, 2007, Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia., Nat Struct Mol Biol, 14, 413, 10.1038/nsmb1235 · DOI · Paper page
  11. MC McNutt, 2007, Catalytic Activity Is Not Required for Secreted PCSK9 to Reduce Low Density Lipoprotein Receptors in HepG2 Cells., J Biol Chem, 282, 20799, 10.1074/jbc.C700095200 · DOI · Paper page
  12. G Dubuc, 2010, A new method for measurement of total plasma PCSK9: clinical applications., J Lipid Res, 51, 140, 10.1194/jlr.M900273-JLR200 · DOI
  13. HJ Kwon, 2008, Molecular basis for LDL receptor recognition by PCSK9., Proc Natl Acad Sci U S A, 105, 1820, 10.1073/pnas.0712064105 · DOI · Paper page
  14. N Nassoury, 2007, The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR., Traffic, 8, 718, 10.1111/j.1600-0854.2007.00562.x · DOI · Paper page
  15. DW Zhang, 2007, Binding of Proprotein Convertase Subtilisin/Kexin Type 9 to Epidermal Growth Factor-like Repeat A of Low Density Lipoprotein Receptor Decreases Receptor Recycling and Increases Degradation., J Biol Chem, 282, 18602, 10.1074/jbc.M702027200 · DOI · Paper page
  16. S Poirier, 2009, Dissection of the endogenous cellular pathways of PCSK9-induced low density lipoprotein receptor degradation: evidence for an intracellular route., J Biol Chem, 284, 28856, 10.1074/jbc.M109.037085 · DOI · Paper page
  17. J Li, 2007, Secreted PCSK9 promotes LDL receptor degradation independently of proteolytic activity., Biochem J, 406, 203, 10.1042/BJ20070664 · DOI
  18. S Benjannet, 2010, Effects of the prosegment and PH on the activity of PCSK9: evidence for additional processing events., J Biol Chem, 285, 40965, 10.1074/jbc.M110.154815 · DOI
  19. DW Zhang, 2008, Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor., Proc Natl Acad Sci U S A, 105, 13045, 10.1073/pnas.0806312105 · DOI · Paper page
  20. L Shan, 2008, PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide., Biochem Biophys Res Commun, 375, 69, 10.1016/j.bbrc.2008.07.106 · DOI · Paper page
  21. A Roubtsova, 2011, Circulating proprotein convertase subtilisin/kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue., Arterioscler Thromb Vasc Biol, 31, 785, 10.1161/ATVBAHA.110.220988 · DOI · Paper page
  22. ON Akram, 2010, Beyond LDL Cholesterol, a New Role for PCSK9., Arterioscler Thromb Vasc Biol, 30, 1279, 10.1161/ATVBAHA.110.209007 · DOI
  23. S Benjannet, 2004, NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol., J Biol Chem, 279, 48865, 10.1074/jbc.M409699200 · DOI · Paper page
  24. KM Timms, 2004, A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree., Hum Genet, 114, 349, 10.1007/s00439-003-1071-9 · DOI
  25. IK Kotowski, 2006, A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol., Am J Hum Genet, 78, 410, 10.1086/500615 · DOI · Paper page
  26. Z Zhao, 2006, Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote., Am J Hum Genet, 79, 514, 10.1086/507488 · DOI
  27. AJ Hooper, 2007, The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population., Atherosclerosis, 193, 445, 10.1016/j.atherosclerosis.2006.08.039 · DOI
  28. NG Seidah, 2009, PCSK9 as a therapeutic target of dyslipidemia., Expert Opin Ther Targets, 13, 19, 10.1517/14728220802600715 · DOI · Paper page
  29. J Genest, 2009, 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations., Can J Cardiol, 25, 567, 10.1016/S0828-282X(09)70715-9 · DOI
  30. X Hua, 1993, SREBP-2, a second basic-helix-loop-helix-leucine zipper protein that stimulates transcription by binding to a sterol regulatory element., Proc Natl Acad Sci U S A, 90, 11603, 10.1073/pnas.90.24.11603 · DOI · Paper page
  31. MS Brown, 1997, The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor., Cell, 89, 331, 10.1016/S0092-8674(00)80213-5 · DOI · Paper page
  32. D Steinberg, 2006, Thematic review series: The Pathogenesis of Atherosclerosis. An interpretive history of the cholesterol controversy, part V: The discovery of the statins and the end of the controversy., J Lipid Res, 47, 1339, 10.1194/jlr.R600009-JLR200 · DOI
  33. PJ Delahoy, 2009, The relationship between reduction in low-density lipoprotein cholesterol by statins and reduction in risk of cardiovascular outcomes: an updated meta-analysis., Clin Ther, 31, 236, 10.1016/j.clinthera.2009.02.017 · DOI
  34. R Kones, 2010, Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease–a perspective., Drug Des Devel Ther, 4, 383, 10.2147/DDDT.S10812 · DOI
  35. TT Abd, 2011, Statin-induced myopathy: a review and update., Expert Opin Drug Saf, 10, 373, 10.1517/14740338.2011.540568 · DOI
  36. G Dubuc, 2004, Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia., Arterioscler Thromb Vasc Biol, 24, 1454, 10.1161/01.ATV.0000134621.14315.43 · DOI · Paper page
  37. AD Attie, 2005, Dual regulation of the LDL receptor–Some clarity and new questions., Cell Metab, 1, 290, 10.1016/j.cmet.2005.04.006 · DOI · Paper page
  38. JF Thompson, 2009, Comprehensive whole-genome and candidate gene analysis for response to statin therapy in the Treating to New Targets (TNT) cohort., Circ Cardiovasc Genet, 2, 173, 10.1161/CIRCGENETICS.108.818062 · DOI
  39. RP Naoumova, 2005, Severe hypercholesterolemia in four British families with the D374Y mutation in the PCSK9 gene: long-term follow-up and treatment response., Arterioscler Thromb Vasc Biol, 25, 2654, 10.1161/01.ATV.0000190668.94752.ab · DOI
  40. KE Berge, 2006, Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy., Arterioscler Thromb Vasc Biol, 26, 1094, 10.1161/01.ATV.0000204337.81286.1c · DOI · Paper page
  41. MJ Graham, 2007, Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice., J Lipid Res, 48, 763, 10.1194/jlr.C600025-JLR200 · DOI
  42. M Frank-Kamenetsky, 2008, Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates., Proc Natl Acad Sci U S A, 105, 11915, 10.1073/pnas.0805434105 · DOI
  43. N Gupta, 2010, A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo., PLoS One, 5, e10682, 10.1371/journal.pone.0010682 · DOI · Paper page
  44. C Dias, 2012, EFFECTS OF AMG 145, A FULLY HUMAN MONOCLONAL ANTIBODY AGAINST PCSK9, ON LOW-DENSITY LIPOPROTEIN CHOLESTEROL IN SUBJECTS TAKING STATINS: A PHASE 1, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, ASCENDING MULTIPLE-DOSE STUDY., J Am Coll Cardiol, 59, E1379-, 10.1016/S0735-1097(12)61380-1 · DOI
  45. YG Ni, 2011, A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivo., J Lipid Res, 52, 78, 10.1194/jlr.M011445 · DOI
  46. JC Chan, 2009, A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates., Proc Natl Acad Sci U S A, 106, 9820, 10.1073/pnas.0903849106 · DOI · Paper page
  47. NG Seidah, 2012, The biology and therapeutic targeting of the proprotein convertases., Nat Rev Drug Discov
  48. G Mayer, 2008, Annexin A2 is a C-terminal PCSK9-binding protein that regulates endogenous low density lipoprotein receptor levels., J Biol Chem, 283, 31791, 10.1074/jbc.M805971200 · DOI · Paper page
  49. DM Waisman, 1995, Annexin II tetramer: structure and function., Mol Cell Biochem, 149–150, 301, 10.1007/BF01076592 · DOI
  50. AB Deora, 2004, An Annexin 2 Phosphorylation Switch Mediates p11-dependent Translocation of Annexin 2 to the Cell Surface., J Biol Chem, 279, 43411, 10.1074/jbc.M408078200 · DOI
  51. CY Chung, 1994, Cell surface annexin II is a high affinity receptor for the alternatively spliced segment of tenascin-C., J Cell Biol, 126, 539, 10.1083/jcb.126.2.539 · DOI
  52. BJ Patchell, 2007, Glycosylation and annexin II cell surface translocation mediate airway epithelial wound repair., Am J Physiol Lung Cell Mol Physiol, 293, L354, 10.1152/ajplung.00412.2006 · DOI
  53. GM Cesarman, 1994, An endothelial cell receptor for plasminogen/tissue plasminogen activator (t-PA). II. Annexin II-mediated enhancement of t-PA-dependent plasminogen activation., J Biol Chem, 269, 21198, 10.1016/S0021-9258(17)31948-8 · DOI
  54. EC Flood, 2011, The annexin A2 system and vascular homeostasis., Vascul Pharmacol, 54, 59, 10.1016/j.vph.2011.03.003 · DOI
  55. Q Ling, 2004, Annexin II regulates fibrin homeostasis and neoangiogenesis in vivo., J Clin Invest, 113, 38, 10.1172/JCI19684 · DOI
  56. A Grefhorst, 2008, Plasma PCSK9 preferentially reduces liver LDL receptors in mice., J Lipid Res, 49, 1303, 10.1194/jlr.M800027-JLR200 · DOI · Paper page
  57. N Nour, 2005, The cysteine-rich domain of the secreted proprotein convertases PC5A and PACE4 functions as a cell surface anchor and interacts with tissue inhibitors of metalloproteinases., Mol Biol Cell, 16, 5215, 10.1091/mbc.E05-06-0504 · DOI
  58. G Mayer, 2004, Sorting of furin in polarized epithelial and endothelial cells: expression beyond the Golgi apparatus., J Histochem Cytochem, 52, 567, 10.1177/002215540405200502 · DOI
  59. RJ Schmidt, 2008, Secreted proprotein convertase subtilisin/kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivo., Biochem Biophys Res Commun, 370, 634, 10.1016/j.bbrc.2008.04.004 · DOI
  60. Y Luo, 2009, Function and distribution of circulating human PCSK9 expressed extrahepatically in transgenic mice., J Lipid Res, 50, 1581, 10.1194/jlr.M800542-JLR200 · DOI
  61. S Benjannet, 2006, The proprotein convertase (PC) PCSK9 is inactivated by furin and/or PC5/6A: functional consequences of natural mutations and post-translational modifications., J Biol Chem, 281, 30561, 10.1074/jbc.M606495200 · DOI · Paper page
  62. G Mayer, 2008, The regulated cell surface zymogen activation of the proprotein convertase PC5A directs the processing of its secretory substrates., J Biol Chem, 283, 2373, 10.1074/jbc.M708763200 · DOI
  63. G Mayer, 2003, Furin interacts with proMT1-MMP and integrin alphaV at specialized domains of renal cell plasma membrane., J Cell Sci, 116, 1763, 10.1242/jcs.00394 · DOI
  64. G Mayer, 2004, The proprotein convertase furin colocalizes with caveolin-1 in the Golgi apparatus and endosomes of hepatocytes., Cell Tissue Res, 316, 55, 10.1007/s00441-004-0866-x · DOI
  65. R Essalmani, 2011, In vivo evidence that furin from hepatocytes inactivates PCSK9., J Biol Chem, 286, 4257, 10.1074/jbc.M110.192104 · DOI · Paper page
  66. JD Horton, 2009, PCSK9: a convertase that coordinates LDL catabolism., J Lipid Res, 50, S172, 10.1194/jlr.R800091-JLR200 · DOI · Paper page
  67. S Crunkhorn, 2011, Trial watch: PCSK9 antibody reduces LDL cholesterol., Nat Rev Drug Discov, 11, 11, 10.1038/nrd3633 · DOI
  68. FB Kraemer, 2007, Adrenal cholesterol utilization., Mol Cell Endocrinol, 265–266, 42, 10.1016/j.mce.2006.12.001 · DOI · Paper page
  69. BR Carr, 1981, Lipoprotein utilization and cholesterol synthesis by the human fetal adrenal gland., Endocr Rev, 2, 306, 10.1210/edrv-2-3-306 · DOI
  70. NC Lucki, 2012, Sphingosine-1-phosphate rapidly increases cortisol biosynthesis and the expression of genes involved in cholesterol uptake and transport in H295R adrenocortical cells., Mol Cell Endocrinol, 348, 165, 10.1016/j.mce.2011.08.003 · DOI
  71. F Du, 2011, Novel domain interaction regulates secretion of proprotein convertase subtilisin/kexin type 9 (PCSK9) protein., J Biol Chem, 286, 43054, 10.1074/jbc.M111.273474 · DOI
  72. PL Surdo, 2011, Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH., EMBO Rep, 12, 1300, 10.1038/embor.2011.205 · DOI · Paper page
  73. N Zelcer, 2009, LXR regulates cholesterol uptake through Idol-dependent ubiquitination of the LDL receptor., Science, 325, 100, 10.1126/science.1168974 · DOI · Paper page
  74. CJ Saris, 1987, cDNA sequence and tissue distribution of the mRNA for bovine and murine p11, the S100-related light chain of the protein-tyrosine kinase substrate p36 (calpactin I)., J Biol Chem, 262, 10663, 10.1016/S0021-9258(18)61015-4 · DOI

Cited by

Sorted by citations

Metadata

Authors
Seidah, N. G., Poirier, S., Denis, M., Parker, R., Miao, B., Mapelli, C., Prat, A., Wassef, H., Davignon, J., Hajjar, K. A., & Mayer, G.
Venue
PLoS ONE
Publisher
Public Library of Science (PLoS)
Published
2012-07-27
Volume
7
Issue
7
Pages
e41865
ISSN
1932-6203
DOI
10.1371/journal.pone.0041865
PMC
PMC3407131
Cited by
117
References
8
Language
en
Licence
creativecommons.org/licenses/by/4.0/ (unspecified)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review